Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has announced the ...

Vertex Pharmaceuticals is a global biotechnology ... a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting ...

sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated ... and is also developing therapies for sickle cell disease, type 1 diabetes, and other conditions.

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...